Global Dl-3-N-Butylphthalide Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

The global Dl-3-N-Butylphthalide market is projected to grow from US$ million in 2025 to US$ million by 2032, at a CAGR of %(2026-2032), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.

The global Dl-3-N-Butylphthalide market size was US$ million in 2025 and is forecast to reach a readjusted size of US$ million by 2032 with a CAGR of %during the forecast period 2026-2032.

The global market for Dl-3-N-Butylphthalide was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of %from 2026 to 2032.

The global Dl-3-N-Butylphthalide market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.

The global market for Dl-3-N-Butylphthalide was estimated to be worth US$ million in 2024 and is forecast to a readjusted size of US$ million by 2031 with a CAGR of %during the forecast period 2025-2031.

The global Dl-3-N-Butylphthalide market is projected to grow from US$ million in 2024 to US$ million by 2031, at a CAGR of %(2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.

The global market for Dl-3-N-Butylphthalide was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

DL-3-n-Butylphthalide is the racemic form of (-)-butylphthalide, a phthalide that has been found in A. graveolens, that has diverse biological activities, including antiplatelet, neuroprotective, and antioxidative properties. DL-3-n-Butylphthalide inhibits ADP-, thrombin-, and arachidonic acid-induced aggregation of isolated washed human platelets when used at concentrations of 30, 100, and 300 µM, respectively. It inhibits the phosphorylation of calcium-dependent cytosolic phospholipase A2 (cPLA2) induced by ADP and reduces thromboxane A2 (TXA2) production induced by thrombin or collagen in isolated washed human platelets at concentrations ranging from 30 to 300 µM. DL-3-n-Butylphthalide also inhibits caspase-3 activation, decreases reactive oxygen species (ROS) production and JNK phosphorylation, and prevents cell death induced by serum deprivation in primary mouse cortical neurons when used at a concentration of 10 µM. It reduces infarct volume, as well as caspase-3 activation and JNK phosphorylation in the peri-infarct region, in a mouse model of right middle cerebral artery occlusion (MCAO) with bilateral common carotid artery ligation when administered at a dose of 100 mg/kg one hour following occlusion.

DL-3-n-Butylphthalide is the racemic form of (-)-butylphthalide, a phthalide that has been found in A. graveolens, that has diverse biological activities, including antiplatelet, neuroprotective, and antioxidative properties. DL-3-n-Butylphthalide inhibits ADP-, thrombin-, and arachidonic acid-induced aggregation of isolated washed human platelets when used at concentrations of 30, 100, and 300 µM, respectively. It inhibits the phosphorylation of calcium-dependent cytosolic phospholipase A2 (cPLA2) induced by ADP and reduces thromboxane A2 (TXA2) production induced by thrombin or collagen in isolated washed human platelets at concentrations ranging from 30 to 300 µM. DL-3-n-Butylphthalide also inhibits caspase-3 activation, decreases reactive oxygen species (ROS) production and JNK phosphorylation, and prevents cell death induced by serum deprivation in primary mouse cortical neurons when used at a concentration of 10 µM. It reduces infarct volume, as well as caspase-3 activation and JNK phosphorylation in the peri-infarct region, in a mouse model of right middle cerebral artery occlusion (MCAO) with bilateral common carotid artery ligation when administered at a dose of 100 mg/kg one hour following occlusion.

DL-3-n-Butylphthalide is the racemic form of (-)-butylphthalide, a phthalide that has been found in A. graveolens, that has diverse biological activities, including antiplatelet, neuroprotective, and antioxidative properties. DL-3-n-Butylphthalide inhibits ADP-, thrombin-, and arachidonic acid-induced aggregation of isolated washed human platelets when used at concentrations of 30, 100, and 300 µM, respectively. It inhibits the phosphorylation of calcium-dependent cytosolic phospholipase A2 (cPLA2) induced by ADP and reduces thromboxane A2 (TXA2) production induced by thrombin or collagen in isolated washed human platelets at concentrations ranging from 30 to 300 µM. DL-3-n-Butylphthalide also inhibits caspase-3 activation, decreases reactive oxygen species (ROS) production and JNK phosphorylation, and prevents cell death induced by serum deprivation in primary mouse cortical neurons when used at a concentration of 10 µM. It reduces infarct volume, as well as caspase-3 activation and JNK phosphorylation in the peri-infarct region, in a mouse model of right middle cerebral artery occlusion (MCAO) with bilateral common carotid artery ligation when administered at a dose of 100 mg/kg one hour following occlusion.